Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avanir's Struggle Was Worth It: Reformulated Zenvia Succeeds In Confirmatory Phase III

This article was originally published in The Pink Sheet Daily

Executive Summary

Once crushed by an FDA approvable letter for the emotional outburst therapy, the company has battled to stay afloat and now anticipates launching the drug in the second half of 2010.

You may also be interested in...



The Winning Combination: Avanir’s Nuedexta Finally Cleared For Emotional Incontinence

Once feared for potentially harmful cardiovascular effects, Avanir Pharmaceuticals Inc.’s Nuedexta has become the first drug to gain FDA approval for treatment of the involuntary emotional disorder “pseudobulbar affect,” with no black box warning.

The Winning Combination: Avanir’s Nuedexta Finally Cleared For Emotional Incontinence

Once feared for potentially harmful cardiovascular effects, Avanir Pharmaceuticals Inc.’s Nuedexta has become the first drug to gain FDA approval for treatment of the involuntary emotional disorder “pseudobulbar affect,” with no black box warning.

Cash Constraints Force Industry To Retool Its Opinion Of PIPEs

Private investments in public equity help firms reach inflection points.

Related Content

Topics

UsernamePublicRestriction

Register

PS069823

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel